{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:02:00Z","timestamp":1789203720738,"version":"build-2803163510"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"7","funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNCI.J"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1093\/jnci\/djw003","type":"journal-article","created":{"date-parts":[[2016,3,5]],"date-time":"2016-03-05T03:14:41Z","timestamp":1457147681000},"page":"djw003","source":"Crossref","is-referenced-by-count":93,"title":["Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States"],"prefix":"10.1093","volume":"108","author":[{"given":"William V.","family":"Padula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie B.","family":"Dusetzina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane F.","family":"Apperley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudiger","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehard","family":"Eigendorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudiger","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois-Xavier","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietger","family":"Niederwieser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Saussele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Schiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Simonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena M.","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,3,4]]},"reference":[{"key":"2016030418591160000_108.7.djw003.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"2016030418591160000_108.7.djw003.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"2016030418591160000_108.7.djw003.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030513"},{"issue":"22","key":"2016030418591160000_108.7.djw003.4","first-page":"1126","article-title":"International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"2016030418591160000_108.7.djw003.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"2016030418591160000_108.7.djw003.6","doi-asserted-by":"crossref","unstructured":"Cortes J Saglio G Baccarani M . Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (Dasision, CA180-056). ASH Annual Meeting Abstracts. 2014;124(21).","DOI":"10.1182\/blood.V124.21.152.152"},{"key":"2016030418591160000_108.7.djw003.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"2016030418591160000_108.7.djw003.8","doi-asserted-by":"crossref","unstructured":"Larson RA Kim DW Issaragrisil S . Efficacy and Safety of Nilotinib vs. Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up of ENESTnd. ASH Annual Meeting Abstracts. 2014;124(21).","DOI":"10.1182\/blood.V124.21.4541.4541"},{"key":"2016030418591160000_108.7.djw003.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"2016030418591160000_108.7.djw003.10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490003"},{"key":"2016030418591160000_108.7.djw003.11","unstructured":"Conti RM . Why are cancer drugs commonly the target of numerous schemes to extend patent exclusivity? Health Affairs Blog. December 4, 2013."},{"key":"2016030418591160000_108.7.djw003.12","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2013.001351"},{"key":"2016030418591160000_108.7.djw003.13","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-2-201301150-00002"},{"key":"2016030418591160000_108.7.djw003.14","doi-asserted-by":"crossref","unstructured":"Conti RM Berndt ER . Specialty drug prices and utilization after loss of US patent exclusivity, 2001\u20132007. In. NBER Working Paper Series 20016: National Bureau of Economic Research (NBER); 2014.","DOI":"10.3386\/w20016"},{"key":"2016030418591160000_108.7.djw003.15","unstructured":"Generic Imatinib. http:\/\/cmlsociety.org\/generic-tyrosine-kinase-inhibitors-tkis-arrive-in-canada\/. Accessed January 30, 2016."},{"key":"2016030418591160000_108.7.djw003.16","doi-asserted-by":"crossref","unstructured":"Dunne S Shannon B Dunne C . A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study. BMC Pharmacol Toxicol. 2013;14:1.","DOI":"10.1186\/2050-6511-14-1"},{"key":"2016030418591160000_108.7.djw003.17","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214522143"},{"key":"2016030418591160000_108.7.djw003.18","doi-asserted-by":"crossref","unstructured":"Gold M Siegel JE Russell LB Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.","DOI":"10.1093\/oso\/9780195108248.001.0001"},{"key":"2016030418591160000_108.7.djw003.19","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.84"},{"key":"2016030418591160000_108.7.djw003.20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-510396"},{"key":"2016030418591160000_108.7.djw003.21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511592"},{"key":"2016030418591160000_108.7.djw003.22","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.305"},{"key":"2016030418591160000_108.7.djw003.23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-532341"},{"key":"2016030418591160000_108.7.djw003.24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-162388"},{"key":"2016030418591160000_108.7.djw003.25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273979"},{"key":"2016030418591160000_108.7.djw003.26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-347575"},{"key":"2016030418591160000_108.7.djw003.27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-477687"},{"issue":"1","key":"2016030418591160000_108.7.djw003.28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1524-4733.2009.00573.x","article-title":"A multinational study of health state preference values associated with chronic myelogenous leukemia","volume":"13","author":"Szabo","year":"2010","journal-title":"Value Health"},{"issue":"6","key":"2016030418591160000_108.7.djw003.29","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.hoc.2014.08.002","article-title":"Chronic Myeloid Leukemia-Transplantation in the Tyrosine Kinase Era","volume":"28","author":"Innes","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"2016030418591160000_108.7.djw003.30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/cob.12041","article-title":"Determining the cost of obesity and its common comorbidities from a commercial claims database","volume":"4","author":"Padula","year":"2014","journal-title":"Clin Obesity"},{"key":"2016030418591160000_108.7.djw003.31","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.862251"},{"key":"2016030418591160000_108.7.djw003.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.04.001"},{"key":"2016030418591160000_108.7.djw003.33","doi-asserted-by":"crossref","unstructured":"Conti RM Padula WV Larson RA . Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU. Ann Hematol. 2015; In Press.","DOI":"10.1007\/s00277-015-2319-x"},{"issue":"Suppl 2","key":"2016030418591160000_108.7.djw003.34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2165\/00019053-199600102-00017","article-title":"Longer patents for increased generic competition in the US. The Waxman-Hatch Act after one decade","volume":"10","author":"Grabowski","year":"1996","journal-title":"Pharmacoeconomics"},{"key":"2016030418591160000_108.7.djw003.35","doi-asserted-by":"publisher","DOI":"10.1086\/467257"},{"issue":"1","key":"2016030418591160000_108.7.djw003.36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1162\/0034653053327694","article-title":"Generic drug industry dynamics","volume":"87","author":"Reiffen","year":"2005","journal-title":"Rev Econ Statistics"},{"key":"2016030418591160000_108.7.djw003.37","doi-asserted-by":"publisher","DOI":"10.1093\/ei\/cbh058"},{"issue":"2","key":"2016030418591160000_108.7.djw003.38","doi-asserted-by":"crossref","first-page":"143","DOI":"10.18553\/jmcp.2011.17.2.143","article-title":"Pharmaceutical step-therapy interventions: a critical review of the literature","volume":"17","author":"Motheral","year":"2011","journal-title":"J Manag Care Pharm"},{"key":"2016030418591160000_108.7.djw003.39","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2014.0516"},{"key":"2016030418591160000_108.7.djw003.40","unstructured":"Pearson CF. Consumers face more hurdles to accessing drugs in exchange plans compared to employer coverage. Washington, DC: Avalere Health; March 2014."},{"issue":"7","key":"2016030418591160000_108.7.djw003.41","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1185\/03007990903044374","article-title":"Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries","volume":"25","author":"Paradis","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"2016030418591160000_108.7.djw003.42","unstructured":"2013\u20132014 Prescription Drug Benefit Costs and Plan Design Report. In: Pharmacy Benefit Management Institute; August 2013; Plano, TX."},{"key":"2016030418591160000_108.7.djw003.43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-309807"},{"key":"2016030418591160000_108.7.djw003.44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"2016030418591160000_108.7.djw003.45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-196543"},{"key":"2016030418591160000_108.7.djw003.46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.9123"},{"key":"2016030418591160000_108.7.djw003.47","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"2016030418591160000_108.7.djw003.48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5797"},{"key":"2016030418591160000_108.7.djw003.49","doi-asserted-by":"crossref","unstructured":"Delphine R Nicolini F Tulliez M . Dasatinib or nilotinib discontinuation in chronic phase-chronic myeloid leukemia patients with durably undetectable BCR-ABL transcripts: Interim analysis of the STOP 2G-TKI study with a minimum follow-up of 12 months \u2013 on Behalf of the French CML Group FILMC. ASH Annual Meeting Abstracts. 2014;124(21).","DOI":"10.1182\/blood.V124.21.811.811"},{"key":"2016030418591160000_108.7.djw003.50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750"},{"key":"2016030418591160000_108.7.djw003.51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1988"},{"key":"2016030418591160000_108.7.djw003.52","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2012.1.122"}],"container-title":["Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/108\/7\/djw003\/17315423\/djw003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T20:00:39Z","timestamp":1718395239000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article-lookup\/doi\/10.1093\/jnci\/djw003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,4]]},"references-count":52,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,3,4]]},"published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1093\/jnci\/djw003"],"URL":"https:\/\/doi.org\/10.1093\/jnci\/djw003","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,4]]}}}